Microbiota–Gut–Brain Axis: Yeast Species Isolated from Stool Samples of Children with Suspected or Diagnosed Autism Spectrum Disorders and In Vitro Susceptibility Against Nystatin and Fluconazole
- 1.3k Downloads
Autism spectrum disorder (ASD) is a general term for a group of complex neurodevelopmental disorders of brain development that limits a person’s ability to function normally. Etiology has not been clearly defined up to date. However, gut microbiota and the bidirectional communication between the gastrointestinal tract and brain, the so-called microbiota–gut–brain axis, are hypothesized, which may be involved in the etiology of several mental disorders. Recent reports suggest that Candida, particularly Candida albicans, growth in intestines may cause lower absorption of carbohydrates and minerals and higher toxin levels which are thought to contribute autistic behaviors. The aim of this study was to identify the 3-year deposited yeasts isolated from stool samples of children with diagnosed or suspected ASD and to determine in vitro activity of nystatin and fluconazole against these isolates using Clinical Laboratory Standards Institute M27-A3 guidelines. A 17-year retrospective assessment was also done using our laboratory records. Among the species identified, intrinsically fluconazole-resistent Candida krusei (19.8 %) and Candida glabrata (14.8 %) with elevated MICs were remarkable. Overall, C. albicans (57.4 %) was the most commonly isolated species in 17 years. The species identification and/or antifungal susceptibility tests have to be performed using the strain isolated from stool sample, to select the appropriate antifungal agent, if antimycotic therapy is needed.
KeywordsNystatin Fluconazole Gut microbiota Microbiota–gut–brain axis Autism spectrum disorders
Compliance with Ethical Standards
The study protocol was approved by Istanbul University Cerrahpasa Medical Faculty Ethics Committee (date: 02.10.2014; No. 41302).
Conflict of interest
- 1.Autism fact sheet. National Institute of neurological disorders and stroke. 2014. http://www.ninds.nih.gov/disorders/autism/detail_autism.htm.
- 2.Watts TJ. The pathogenesis of autism. Clin Med Pathol. 2008;1(99):103.Google Scholar
- 11.Norris S. Potential causes of autism spectrum disorders. Rep Can Libr Parlim. 2006:4–5.Google Scholar
- 14.Hazen KC, Howell SA. Candida, Cryptococcus and other yeasts of medical importance. In: Murray R, Baron EJ, Jorgensen JH, Phaller MA, Yolken RH, editors. Manual of clinical microbiology, vol. 9., ASM PressDC: Washington; 2007. p. 1762–88.Google Scholar
- 15.Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, in 3rd Informal Supplement M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.Google Scholar
- 16.CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth International Supplement, M27-A3, Wayne, PA: Clinical and Laboratory Standards Institute, 2012: 32.Google Scholar
- 30.Rozkiewich D, Daniluk T, Sciepuk M, Kurzqkowska B, Oldak E, Zaremba ML. Prevalence of Candida albicans in stool of hospitalized children in 2003 with or without diarrhea from the Bialystok region. Prz Epidemiol. 2005;59(1):43–51.Google Scholar
- 34.De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serazzanetti DI, Cristofori F, Guerzoni ME, Gobbetti M, Francavilla R. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS ONE. 2013;8(10):e76993. doi: 10.1371/journal.pone.0076993.PubMedCentralCrossRefPubMedGoogle Scholar
- 36.Kreger-Van Rij NJW, editor. The yeasts: a taxonomic study. 3rd ed. Amsterdam: Elsevier Science Publishers B.V; 1984.Google Scholar
- 38.Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize resistance in the SENTRY antimicrobial surveillance programme (2009). Diagn Microbiol Infect Dis. 2011;69(1):45–50.CrossRefPubMedGoogle Scholar
- 39.Carrillo-Munoz AJ, Quindos G, Tur C, et al. In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother. 1999;44(3):397–401.CrossRefPubMedGoogle Scholar